Calidi Biotherapeutics, Inc. (CLDI)

Market Cap	26.27M
Revenue (ttm)	n/a
Net Income (ttm)	-27.95M
Shares Out	19.32M
EPS (ttm)	-5.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,436,691
Open	1.350
Previous Close	1.450
Day's Range	1.270 - 1.490
52-Week Range	0.141 - 3.890
Beta	1.05
Analysts	Strong Buy
Price Target	16.67 (+1,125.74%)
Earnings Date	Nov 12, 2024

About CLDI

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, m...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 41
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CLDI
• Website: https://www.calidibio.com

Analyst Forecast

According to 3 analysts, the average rating for CLDI stock is "Strong Buy." The 12-month stock price forecast is $16.67, which is an increase of 1,125.74% from the latest price.

Price Target

$16.67

(1,125.74% upside)

Analyst Consensus: Strong Buy